Selecta Biosciences Presents Full Data from Phase 2 Trial of SEL-212 for Chronic Refractory Gout at EULAR 2019

World News: . []

WATERTOWN Mass June 12 2019 GLOBE NEWSWIRE -- LINK  SELB a clinical-stage biotechnology company focused on LINK  the full potential of biologic LINK  based on its immune tolerance LINK  technology ImmTOR will present fu ll data...

More news and information about Selecta Biosciences, Inc.

Published By:

Globe Newswire: 13:00 GMT Wednesday 12th June 2019

Published: .

Search for other references to "selecta" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us